Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.

By B. Nemets, Z. Stahl, R. Belmaker. American Journal of Psychiatry, 2002

632 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015, background): “There is some evidence for the use of EPA or EPA+DHA/fish oil as adjunctive treatment in three RCTs in depression not responding to antidepressants (Nemets et al., 2002; Peet and Horrobin, 2002; Su et al., 2003).”
Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021 (2021, background): “384 Similarly, EPA (2 g/day for 4 weeks) improved symptoms in patients with unipolar de- 385 pressive disorder [105].”
The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. (2004, background): “In a double-blind RCT of EPA, patients with unipolar depressive disorder experienced significant improvements in symptoms after 4 weeks of treatment (Nemets et al., 2002).”
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. (2006, methodology): “Nemets et al.63 found significant antidepressant effects using ethyl ester EPA (2 g/day) in a placebocontrolled adjunctive study for refractory depression.”
Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases (2011, background): “In some trials, supplementation with long chain n-3 PUFAs has been shown to improve mood in patients with major depression and bipolar disorder [271–274].”